MONOGRAPH

VinBLASTine

Scope (Staff):	Medical, Pharmacy, Nursing
Scope (Area):	All Clinical Areas

Child Safe Organisation Statement of Commitment

CAHS commits to being a child safe organisation by applying the National Principles for Child Safe Organisations. This is a commitment to a strong culture supported by robust policies and procedures to reduce the likelihood of harm to children and young people.

This document should be read in conjunction with this DISCLAIMER

⚠ HIGH RISK MEDICINE ⚠

QUICKLINKS

Dosage/Dosage Adjustments	Administration	Compatibility	Monitoring

DRUG CLASS

Vinca alkaloid.[1]

VinBLASTine is a High Risk Medicine.

VinBLASTine is a Cytotoxic Medicine.

Extravasation: Vinblastine is a vesicant. Refer to Extravasation of Antineoplastic (Cytotoxic) Agents Guideline.

Emetogenic Rating: Minimal. Refer to Chemotherapy Induced Nausea and Vomiting (CINV) Management Guideline.

INDICATIONS AND RESTRICTIONS

- VinBLASTine can only be prescribed by Oncologists or Haematologists as per protocol for the treatment of malignancy.

CONTRAINDICATIONS

VinBLASTine is fatal if given intrathecally.[1, 2]

- Hypersensitivity to vinBLASTine or any component of the formulation.

PRECAUTIONS

- VinBLASTine is a cytotoxic medication and must be handled with care. Extra vigilance is required regarding the safe preparation, administration and monitoring of cytotoxic medications.
- VinBLASTine MUST NOT be delivered to the patient at the same time as medications intended for central nervous system administration.[3]
- VinBLASTine is a vesicant, therefore care should be taken to ensure that the needle or catheter is positioned securely within the vein to avoid the risk of extravasation.[3, 4]

FORMULATIONS

Listed below are products available at PCH, other formulations may be available, check with pharmacy if required:

- 10 mg/10 mL vials.[2]

DOSAGE & DOSAGE ADJUSTMENTS

Dosage as per treatment protocol in the OIMS (Oncology Information Management System).

Renal impairment:

- No dosage adjustment is necessary for renal impairment.[3]

Hepatic impairment:

- Dosage adjustment may be necessary for patients with hepatic insufficiency.[1, 3] Adjust the dose as per treatment protocol.

Treatment related toxicity:

- Dose adjustment as per treatment protocol.

RECONSTITUTION & ADMINISTRATION

Handle as cytotoxic.

VinBLASTine must be compounded by Pharmacy Compounding Services (PCS) in a cytotoxic drug safety cabinet by pharmacy personnel who have appropriate training and validation in aseptic and cytotoxic drug reconstitution and handling techniques.

VinBLASTine is to be compounded in a minibag (**NOT** a syringe) to prevent accidental intrathecal administration.[5]

A warning label **"WARNING – For intravenous use ONLY. Fatal if given by any other route"** must be attached to the IV minibag and outer bag of all VinBLASTine products.[1,5]

Preferable to administer via central line or large peripheral vein.[4]

VinBLASTine must always be administered intravenously. Fatal if given by any other route.[1, 2]

Intravenous infusion: Administer over 5 to 10 minutes or as per treatment protocol;[1, 5] prolonged administration (≥ 30 to 60 minutes) may increase the risk of extravasation.[3]

COMPATIBILITY *(LIST IS NOT EXHAUSTIVE)*

Compatible fluids:

Glucose 5%, sodium chloride 0.9%.[2, 6]

Compatible and INCOMPATIBLE drugs:

Antineoplastic therapies are not routinely administered with other medications. Consult two or more drugs references *(Compatibilities of IV drugs)* or pharmacy when there is a requirement for medications to be given concurrently.

MONITORING

- Monitor complete blood count and liver function.[1]
- Monitor for signs of neuropathy,[8] including asymptomatic depression of Achilles reflex (i.e. foot drop).[1]
- Monitor infusion site.[8]

ADVERSE EFFECTS

Common: Myelosuppression, alopecia.[9]

Infrequent: Constipation, loss of deep tendon reflexes, gonadal suppression resulting in amenorrhoea or azoospermia.[9]

Rare: Bronchospasm and dyspnoea, hyperuricemia or uric acid nephropathy, nausea, vomiting, anorexia, bone pain, rashes, photosensitivity, epidermal necrosis (extravasation injury), phlebitis, myocardial infarct, hypertension, Raynaud's phenomenon, arrhythmia, headache, tinnitus, seizures, syndrome of inappropriate antidiuretic hormone secretion (SIADH), bone pain, weakness, jaw pain, malaise, stomatitis, paraesthesia, peripheral neuritis, ototoxicity, vestibular and auditory damage to the eighth cranial nerve (partial or total deafness that may be temporary or permanent, difficulties with balance including dizziness, nystagmus, and vertigo), depression, abdominal pain, diarrhoea, pharyngitis, paralytic ileus, haemorrhagic enterocolitis, peptic ulcer and/or rectal bleeding, urinary retention, transient hepatitis, pulmonary infiltrates, hoarseness, ptosis, diplopia.[9]

STORAGE

Vial: Store at 2˚ to 8°C. Do not freeze. Protect from light.[2]

Diluted solution (manufactured by PCS in PVC bags): Store at 2˚ to 8˚C for up to 7 days. Do not freeze.[10]

INTERACTIONS

This medication may interact with other medications; consult PCH approved references (e.g. Clinical Pharmacology), a clinical pharmacist or PCH Medicines Information Service on extension 63546 for more information.

Please note: The information contained in this guideline is to assist with the preparation and administration of **vinBLASTine**. Any variations to the doses recommended should be clarified with the prescriber prior to administration

Related CAHS internal policies, procedures and guidelines

Extravasation of Antineoplastic (Cytotoxic) Agents Guideline

Cytotoxic Biotherapy Agents Administration

Cytotoxic Biotherapy Agents Safety

Chemotherapy Induced Nausea and Vomiting Management

Related external legislation, policies and guidelines

Mandatory Standard for Vinca Alkaloids

References

1. Australian Medicines Handbook [online]. Adelaide (SA): Australian Medicines Handbook Pty Ltd; [cited August 2022].
2. MIMS Medicines Information. St Leonards (NSW): MIMS Australia Pty Ltd. DBL Vinblastine Injection (revised August 2021), [cited September 2022].
3. Vinblastine: Drug information [Internet]. UpToDate. [cited September 2022]. Available from: https://www-uptodate-com.pklibresources.health.wa.gov.au/contents/vinblastine-drug-information.
4. Extravasation Reference [Internet]. Children's Oncology Group. 2015 [cited September 2022]. Available from: https://www.cogmembers.org/_files/disc/Nursing/ExtravasationReference.pdf.
5. Australian Injectable Drugs Handbook. Collingwood (VIC): The Society of Hospital Pharmacists of Australia; [cited September 2022].
6. ASHP® Injectable Drug Information™ - 2021 Edition. Bethesda, Maryland: American Society of Health-System Pharmacists®; [cited October 2022].
7. Vinblastine: IV Compatibility [Internet]. Clinical Pharmacology. [cited October 2022]. Available from: https://www-clinicalkey-com.pklibresources.health.wa.gov.au/pharmacology/monograph/645?sec=monivco.
8. Parenteral Chemotherapy Administration Guidelines used by the Children's Oncology Group [Internet]. Children's Oncology Group. 2020 [cited October 2022]. Available from: https://www.cogmembers.org/_files/disc/Pharmacy/ChemoAdminGuidelines.pdf.
9. Drug Information for Commercial Agents used by the Children's Oncology Group [Internet]. Children's Oncology Group. 2022 [cited October 2022]. Available from: https://www.cogmembers.org/_files/disc/Pharmacy/CommercialAgentsMonographs.pdf.
10. Vinblastine sulfate [Internet]. Stabilis. [cited October 2022]. Available from: https://www.stabilis.org/Monographie.php?IdMolecule=93.

This document can be made available in alternative formats on request for a person with a disability.

File Path:	W:\Safety & Quality\CAHS\CLOVERS MEDICAL Pharmacy\Procedures Protocols and Guidelines\Medication Monographs_Word\PCH.MED.VinBLASTine.docx		
Document Owner:	Chief Pharmacist		
Reviewer / Team:	Pharmacist, Ward 1A Clinical Nurse Manager, Oncology Consultant		
Date First Issued:	Jul 2019	**Last Reviewed:**	Jun 2023
Amendment Dates:	*Jul 2023*	**Next Review Date:**	Jul 2026
Approved by:	CAHS Medication Safety Committee	**Date:**	Jun 2023
Endorsed by:	CAHS Drug & Therapeutics Committee	**Date:**	Jul 2023
Standards Applicable:	NSQHS Standards: NSMHS: N/A Child Safe Standards: N/A		

Printed or personally saved electronic copies of this document are considered uncontrolled

Healthy kids, healthy communities

Compassion | Excellence | Collaboration | Accountability | Equity | Respect

Neonatology | Community Health | Mental Health | Perth Children's Hospital